These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23188799)

  • 1. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
    Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.
    Zhang T; Shen H; Dong W; Qu X; Liu Q; Du J
    Sci Rep; 2014 Oct; 4():6855. PubMed ID: 25358597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
    Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
    PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer.
    Cao H; Dong W; Shen H; Xu J; Zhu L; Liu Q; Du J
    PLoS One; 2015; 10(8):e0135844. PubMed ID: 26287334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor.
    Zheng H; Worrall C; Shen H; Issad T; Seregard S; Girnita A; Girnita L
    Proc Natl Acad Sci U S A; 2012 May; 109(18):7055-60. PubMed ID: 22509025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
    Cao H; Dong W; Qu X; Shen H; Xu J; Zhu L; Liu Q; Du J
    Sci Rep; 2016 Aug; 6():31072. PubMed ID: 27488947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase.
    Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Girnita A; Lefkowitz RJ; Larsson O
    J Biol Chem; 2005 Jul; 280(26):24412-9. PubMed ID: 15878855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
    Olmos D; Postel-Vinay S; Molife LR; Okuno SH; Schuetze SM; Paccagnella ML; Batzel GN; Yin D; Pritchard-Jones K; Judson I; Worden FP; Gualberto A; Scurr M; de Bono JS; Haluska P
    Lancet Oncol; 2010 Feb; 11(2):129-35. PubMed ID: 20036194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes.
    Suleymanova N; Crudden C; Shibano T; Worrall C; Oprea I; Tica A; Calin GA; Girnita A; Girnita L
    Oncogene; 2017 Oct; 36(41):5734-5744. PubMed ID: 28581517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1.
    Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
    Oncogene; 2008 Mar; 27(11):1629-38. PubMed ID: 17828296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
    Garofalo C; Mancarella C; Grilli A; Manara MC; Astolfi A; Marino MT; Conte A; Sigismund S; Carè A; Belfiore A; Picci P; Scotlandi K
    Mol Endocrinol; 2012 Sep; 26(9):1603-16. PubMed ID: 22798295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor.
    Girnita A; Zheng H; Grönberg A; Girnita L; Ståhle M
    Oncogene; 2012 Jan; 31(3):352-65. PubMed ID: 21685939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth.
    Crudden C; Shibano T; Song D; Dragomir MP; Cismas S; Serly J; Nedelcu D; Fuentes-Mattei E; Tica A; Calin GA; Girnita A; Girnita L
    Cancer Res; 2021 Jan; 81(2):501-514. PubMed ID: 33158816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression.
    Girnita L; Shenoy SK; Sehat B; Vasilcanu R; Vasilcanu D; Girnita A; Lefkowitz RJ; Larsson O
    J Biol Chem; 2007 Apr; 282(15):11329-38. PubMed ID: 17303558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
    Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
    Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
    Girnita L; Wang M; Xie Y; Nilsson G; Dricu A; Wejde J; Larsson O
    Anticancer Drug Des; 2000 Feb; 15(1):67-72. PubMed ID: 10888037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.